Teva’s Anti-IL-15 Drug Shows Promise in Celiac Disease Trial
Event summary
- Teva’s TEV ‘408, an anti-IL-15 monoclonal antibody, met primary endpoint in Phase 2a celiac disease trial, showing statistically significant prevention of gluten-induced intestinal damage vs. placebo.
- The study enrolled 50 adults with celiac disease, with TEV ‘408 demonstrating a treatment difference of 0.45 in Vh:Cd ratio (p<0.05) and favorable effects on intestinal inflammation and symptoms.
- TEV ‘408 was well-tolerated with no safety signals observed, supporting its potential as a pipeline-in-a-product opportunity in multiple diseases.
- Teva secured up to $500 million in funding from Royalty Pharma in January 2026 to accelerate TEV ‘408’s clinical development.
The big picture
Teva’s positive Phase 2a results for TEV ‘408 in celiac disease validate its strategy of targeting the IL-15 pathway for immune-mediated diseases. The success of this trial, combined with ongoing vitiligo studies, positions TEV ‘408 as a potential blockbuster asset. The $500 million funding agreement with Royalty Pharma underscores the market’s confidence in Teva’s ability to execute on its Pivot to Growth strategy, shifting from generics to innovative biopharmaceuticals.
What we're watching
- Pipeline Diversification
- Whether Teva can leverage TEV ‘408’s success in celiac disease to expand its pipeline-in-a-product strategy into other immune-mediated conditions like vitiligo.
- Regulatory Pathway
- The pace at which TEV ‘408 advances through late-stage trials and secures regulatory approvals, particularly given its Fast Track designation for celiac disease.
- Commercialization Strategy
- How Teva plans to monetize TEV ‘408, including potential partnerships or licensing deals, following its strategic funding agreement with Royalty Pharma.
Related topics